Biological medicines have revolutionised the treatment of Crohn's disease [CD]. Yet, the management of patients not responding to tumour necrosis factor [TNF] antagonists remains a clinical challenge. Ustekinumab is a human monoclonal antibody blocking the biological activity of interleukins 12 and 23, which regulate the immune system and immune-mediated inflammatory disorders. Ustekinumab has recently been approved for the treatment of adult patients with moderately to severely active CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist, or have medical contraindications to such therapies. Herein, we review the new biological drug's efficacy and safety data reported from randomised controlled trials and real-world observational studies conducted in populations with CD, in order to identify the patient groups most likely to benefit, and to appropriately place ustekinumab into treatment algorithms for CD.
Introduction
Crohn's disease [CD] is a chronic inflammatory disorder of the gastrointestinal tract, characterised by transmural inflammation, a discontinuous distribution pattern, a tendency to form fibrotic strictures and fistulas, and periods of disease activity alternating with periods of disease remission. Though typically affecting distal ileum, ileocaecal region, colon and the perianal region, it may involve any segment of the digestive tract. 1 The medical armamentarium for the treatment of CD has significantly expanded during past years, and includes steroids, immunosuppressants [thiopurines and methotrexate], and biological therapies, ie tumour necrosis factor [TNF] antagonists [adalimumab, certolizumab pegol, and infliximab] and the anti-integrin antibodies [natalizumab and vedolizumab] . 2 Current therapies aim for a deep and prolonged remission with the goal of preventing complications and halting the progressive course of disease. 3 Despite the variety of available treatments, a sizeable proportion of patients with CD suffer continuing symptoms and/or inflammation, often leading to disability, quality of life deterioration, and need for intestinal surgery. 4 Currently, there remain limited therapeutic options for the management of those CD patients who have failed biological therapies, either because of a lack of response to initial treatment [primary nonresponse] or due to a secondary loss of response that requires dose escalation or a switch to another treatment [secondary nonresponse]. 5 To address this clinical challenge, additional therapeutic agents targeting alternative disease mechanisms are needed.
Ustekinumab is a novel monoclonal antibody targeting the p40 subunit of interleukin-12 and interleukin-23 , which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. 6 Ustekinumab has recently been approved by the European Medicines Agency, 7 the United States Food and Drug Administration, 8 and Health Canada, 9 for the treatment of adult patients with moderately to severely active CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist or have medical contraindications to such therapies. After an intravenous infusion for induction, ustekinumab is administered subcutaneously for maintenance therapy. Yet, the place of ustekinumab in the CD treatment algorithms is not clear. Positioning requires careful consideration of the drug's safety and efficacy profile together with the characteristics of the CD populations studied. Hence, we reviewed the evidence about ustekinumab use in CD, in a systematic manner [Box 1], to gain insight on how this new biological drug can be integrated into clinical practice.
Mechanism of Action
IL-12 and IL-23 are two important pro-inflammatory cytokines that are involved in the pathophysiology of CD. [10] [11] [12] [13] [14] [15] Monoclonal antibody neutralisation of IL-12 and IL-23, through their common p40 subunit, has demonstrated efficacy in treating animal models of colitis. [16] [17] [18] [19] Indeed, a genome-wide association study was confirmatory of the murine immunological evidence, and linked the pathogenesis of CD with the IL-12/IL-23 inflammation pathway. 20 Ustekinumab is a fully human immunoglobulin G1 [IgG1] kappa monoclonal antibody that blocks the biological activity of IL-12 and IL-23 by inhibiting their receptors on T cells, natural killer cells, and antigen-presenting cells, and thus downregulates aspects of the immune system that are considered to be central to the pathology of CD. 21 
Efficacy in Randomised Controlled Trials
Evidence from clinical trials evaluating ustekinumab in CD [ Table 1 ] will be discussed.
Phase 2a study
The first study investigating the clinical efficacy of ustekinumab in the treatment of moderate-to-severe CD was a phase 2a clinical trial conducted in anti-TNF-naïve and anti-TNF-experienced patients. 22, 23 In the double-blind, placebo-controlled, parallel-group, cross-over component of this trial [population 1; n = 104] patients were randomly assigned [1:1 Table 2 ]. Nevertheless, in a subgroup of patients who were previously given infliximab [neither primary nor secondary nonresponders; n = 49], a higher clinical response rate was noted over 8 weeks [59% versus 26%; P = 0.022]. 22 In the open-label component of this study, a second population comprising primary and secondary nonresponders to infliximab [population 2; n = 27] was randomly assigned to receive CD, Crohn's disease; IV, intravenous; PBO, placebo; q8w, every 8 weeks; q12w, every 12 weeks; SC, subcutaneous; TNF, tumour necrosis factor; UST, ustekinumab; wks, weeks; wk, Week.
Box 1. Evidence search process
We searched for relevant publications using PubMed, Scopus, and the Cochrane Library from their inception until March 5, 2017 . The search combined the terms 'ustekinumab' and 'Crohn's disease'. We critically reviewed articles published in English, and gave priority to randomised controlled trials, real-world studies, and meta-analyses. Case reports and studies pertaining to non-human subjects were excluded. Finally, we searched the bibliographies of included articles, the ClinicalTrials.gov, to ensure identification of all relevant trials, and also considered abstracts presented at major meetings.
either a single 4.5 mg/kg IV ustekinumab infusion, or four weekly 90-mg SC injections. Numerically higher rates of clinical response were seen with IV as compared with SC administration [54% versus 43%]; however, this finding did not reach statistical significance. 22 3.2. Phase 2b CERTIFI study 24, 25 Subsequently, a 36-week, phase 2b, randomised, double-blind, parallel-group, placebo-controlled trial was performed in adult patients with moderate-to-severe CD that was resistant to anti-TNF treatment [primary or secondary nonresponders or intolerant]. 24 Following these phase 2 studies, three phase 3 clinical trials were conducted [UNITI phase 3 programme; Table 1 and Figure 1 ]. [26] [27] [28] [29] 3.3. Phase 3, UNITI-1 study 26, 27 UNITI-1 was a multicentre, phase 3, parallel-group, double-blind, placebo-controlled study evaluating the efficacy and safety of ustekinumab in moderately to severely active CD in patients who had failed or were intolerant to one or more anti-TNF agents. Table 1 , Figure 1 ]. The primary endpoint was clinical response at Week 6 [defined as a ≥ 100-point decrease from the baseline CDAI score, or as a CDAI < 150 for patients with a baseline score ≤ 248]. The results were in favour of ustekinumab [ Table 2 ]. Clinical response at Week 6 was seen in 33.7% of the 6-mg group, and 34.3% of the p130-mg group, compared with 21.5% in the placebo group [P = 0.003 and pP = 0.002, respectively]. In addition, the secondary induction endpoints of clinical remission and response at Week 8 were met [for both ustekinumab groups versus placebo]. 26 3.4. Phase 3 UNITI-2 study 26, 28 UNITI-2 was another multicentre, phase 3, parallel-group, doubleblind, placebo-controlled trial evaluating the efficacy and safety of ustekinumab induction specifically in patients with moderately to severely active CD, who had previously failed conventional treatments [ie corticosteroids and/or immunomodulators] and were either naïve to or had been exposed to anti-TNF agents, but had not failed such biological therapy. 26, 28 Similarly to the UNITI-1 trial, participants [n = 628] were randomised [1:1:1] to receive either a single IV infusion of ustekinumab 130 mg, or a weight-based dose of approximately 6 mg per kg of body weight, or placebo, and were followed up for 8 weeks [ Table 1 , Figure 1 ]. In the UNITI-2 study, higher proportions of patients assigned to ustekinumab 130 mg [ Table 2 ]. The absolute between-group differences regarding the clinical remission rates at Week 44 observed in the UNITI-1 subgroup [patients who met the criteria for primary or secondary nonresponse or had unacceptable side effects when treated with TNF antagonists] were similar to those observed in the total population analysed [ie patients from both UNITI-1 and UNITI-2 studies] but were not significant.
Regarding secondary endpoints, more patients in the ustekinumab groups experienced clinical response [Week 44: 59.4% and 58.1% in the q8w and q12w groups, respectively, versus 44.3% in the placebo group; p < 0.05 for both comparisons], as well as corticosteroid-free remission [Week 44: 46.9% and 42.6% in the q8w and q12w groups, respectively, versus 29.8% in the placebo group; p < 0.05 for both comparisons]. Overall, the q8w regimen consistently showed higher efficacy than the q12w regimen across several endpoints. 26 After Week 44, all participants who continued to maintain clinical response were eligible to continue receiving ustekinumab until Week 252 [IM-UNITI long-term extension study]. Interim data analysis showed that ustekinumab treatment maintained clinical response and remission for up to 2 years, with no new safety signals observed. 
Safety in Randomised Controlled Trials
There have always been safety concerns regarding the biological agents, specifically focusing on the risks of infections and neoplasia. [31] [32] [33] [34] [35] Regarding ustekinumab, long-term safety experience has been obtained in patients with moderate to severe psoriasis and multiple sclerosis. [36] [37] [38] [39] Although the patient populations and dosing are different from those in CD, the drug appears to be safe, which is very important given the role of IL-12 and IL-23 in maintaining immune homeostasis.
Similarly, the rates of adverse events, serious adverse events, infections, serious infections, and administration site reactions reported in the randomised, placebo-controlled trials of ustekinumab in CD appear to be comparable across treatment and placebo groups [ Table 3 ]. [22] [23] [24] [25] [26] [27] [28] [29] Moreover a Cochrane review, which synthesised data from randomised controlled trials of anti-IL-12/23p40 antibodies for induction of remission in CD, indicated no significant differences between ustekinumab and placebo in the risk of adverse events (risk ratio 0.97, 95% confidence interval [CI]: 0.90-1.04; high quality evidence) and serious adverse events [risk ratio 0.83, 95% CI: 0.58-1.20; moderate quality evidence]. 40 On the other hand, it remains uncertain whether ustekinumab might be associated with an increase in the risk of developing malignancies. Studies of genetically deficient IL-12/IL-23 mice, or neutralising IL-12/IL-23 antibodies in mouse tumour models, have suggested that there may be an increased risk of malignancy with antagonism of IL-12/IL-23 activity. 41, 42 However, the evidence currently available is insufficient to draw definitive conclusions. Cancer data derived from clinical trials are sparse. Moreover, the participants' exposure and follow-up times are very short compared with the time needed for cancer to develop.
Immunogenicity
In the phase 2a study, 22 no anti-ustekinumab antibodies were identified in samples taken from 99 participants. In the phase 2b CERTIFI study, 24 anti-ustekinumab antibodies were detected in three [0.7%] of 427 patients exposed to the drug through Week 36. Likewise, only two patients [0.2%], who had received ustekinumab 130 mg IV in the UNITI-1 and UNITI-2 phase 3 studies, 26 were found positive for antidrug antibodies, as well as 27 of 1154 patients [2.3%] in the IM-UNITI phase 3 study through Week 44. 26 Antidrug antibodies were evaluated by means of a drug-tolerance assay. Given that immunogenicity data are highly dependent on the sensitivity and specificity of the assay, comparison of the incidence of antibodies to ustekinumab with the incidence of antibodies to other products may be misleading.
Real-world Experience
Gastroenterologists' early experience with ustekinumab through compassionate release programmes [preceding regulatory approval for the treatment of adult patients with moderately to severely active CD] has been reported in few studies from North America and Europe. Herein we summarise real-world observational studies having reported their data in full-text publications. [43] [44] [45] [46] [47] 
Ma and co-workers, 2017
This retrospective cohort study, performed in Canada, showed ustekinumab to be effective for achieving short-term and long-term steroid-free clinical, endoscopic, and radiographic response and remission outcomes in CD patients failing multiple biological agents. In total, 167 patients treated with ustekinumab were analysed [median follow-up was 46 weeks; 95% of patients had previously failed TNF antagonists]. At 3 months, clinical response [reduction in Harvey Bradshaw Index [HBI] of ≥ 3 points] was achieved in 39% and remission [HBI ≤ 4 points] in 15% of patients. At 6 months, clinical response was achieved in 60% and remission in 25% of patients. At 12 months, clinical response was achieved in 60% and remission in 28% of patients. Endoscopic or radiographic response (as assessed by ileocolonoscopy, contrast-enhanced ultrasound, or computed tomography/magnetic resonaonce [CT/MR] enterography) was demonstrated in 55% of patients at 6 months and 56% of patients at 12 months. Endoscopic response was defined by an improvement in mucosal inflammation compared with baseline with, at minimum, resolution of deep ulcerations, and radiographic response was defined by improvement in bowel wall thickness, inflammatory fat, mural blood flow, and hyper-enhancement compared with baseline imaging by physician global assessment. 43 On the other hand, ustekinumab was found to be reasonably safe: 31% of patients experienced an adverse event while on treatment, with most of them being infections [12%], and serious adverse events requiring drug discontinuation or hospitalisation were rather uncommon [7%]. 43 
Khorrami and co-workers, 2016
This retrospective open-label study across 42 Spanish tertiary IBD centres analysed 116 CD patients who were resistant to at least one conventional immunosuppressant and one TNF antagonist. Median patient follow-up was 10 months. Clinical response [decrease in HBI score by ≥ 3 points from baseline] after loading ustekinumab was achieved in 84% of patients. The clinical benefit at 6 months, 12 months, and end of follow-up was 76%, 64%, and 58%, respectively. Dose escalation was required in 10% of the patients, and was effective in 73% of them. The drug was generally safe. 44 
Wils and co-workers, 2016

Harris and co-workers, 2016
In this retrospective chart review performed in two academic North American medical centres, 45 patients with complicated refractory CD were studied. Patient outcomes were evaluated at a minimum of 90 days from the initiation of ustekinumab: 46% of patients achieved clinical response [decrease in HBI score of ≥ 3 points] and 35% achieved clinical remission [HBI score ≤ 3]; endoscopic response was seen in 76%, and complete endoscopic remission in 24% of the patients. 46 
Kopylov and co-workers, 2014
This retrospective analysis reported the real-life experience with ustekinumab off-label use in 38 anti-TNF resistant CD patients treated at McGill University, Montreal, Canada. An initial clinical response [defined by physician's global assessment combined with decision to continue therapy] was achieved by 74% of the patients receiving ustekinumab. The initial response was successfully maintained in the majority of patients for up to 12 months [80% of the initial responders maintained their response for 6 months, and 89% of patients responding at 6 months maintained their disease status to 12 months of follow-up]. Dose escalation was necessary in 48% of patients, and was successful in 61% of them. Regarding harms, only one serious adverse event [a Clostridium difficile infection] was reported. 47 
Comparison of Ustekinumab Versus Other Biologics
Comparative assessment of ustekinumab versus other biologics for the treatment of patients with CD is challenging because direct, head-to-head trials are lacking. Evidence on comparative efficacy and safety can be obtained only through network meta-analyses; however, great caution is needed because indirect treatment comparisons may be undermined by the presence of clinical and methodological heterogeneity among the registration, placebo-controlled trials of different biologics. 48 A recent systematic review, comparing ustekinumab versus other biological agents [adalimumab, infliximab, and vedolizumab] for the treatment of adult patients with moderate-tosevere CD, included 12 placebo-controlled trials; there were no direct head-to-head studies. 49 Evidence from indirect treatment comparison [performed within a Bayesian framework] suggested comparable efficacy for remission or response at 12 months with ustekinumab versus adalimumab, infliximab, and vedolizumab, both in patients who had failed conventional therapy and in patients who had failed anti-TNF therapy. None of the comparisons of ustekinumab to its biologic comparators was statistically significant [all credible intervals of the odds ratios included the unit value]. 49 Similarly, another recent network meta-analysis investigating the comparative safety profile of biological therapies in patients with CD [infliximab, adalimumab, vedolizumab, certolizumab pegol, and ustekinumab] demonstrated no significant differences in the risk of adverse events. 50 Nevertheless, given the important limitations of indirect-comparison methods, direct head-to-head trials between biological medicines should be a top priority on the research agenda to clarify the comparative efficacy and harm of alternative biological therapies for CD.
Positioning Ustekinumab in the Treatment of Crohn's Disease
Currently, the biologics with regulatory approval for the management of CD include: TNF antagonists [adalimumab, certolizumab pegol, and infliximab], anti-integrin drugs [natalizumab and vedolizumab], and ustekinumab. The accumulated evidence with ustekinumab use shows that this novel agent is efficacious for induction and maintenance of remission in patients with moderate-to-severe CD. Moreover, it has demonstrated a favourable safety profile. So, the question of where ustekinumab fits in the algorithms of CD treatment comes up.
TNF antagonists are currently positioned as first-line biologic therapy in the management of moderate-to-severe CD. 51 However, a considerable number of patients do not have a response to treatment with these agents, and among those who do have a response, it is often not sustained or unacceptable adverse effects require treatment discontinuation. For such patients, the benefit of using a second TNF antagonist may be limited. [52] [53] [54] Doubtless, ustekinumab is broadening the therapeutic landscape for patients who have an inadequate response with, lost response to, are intolerant to, or have medical contraindications to treatment with a TNF antagonist. Inhibition of a parallel inflammatory pathway, such as the IL-12/IL-23 cytokine pathway, may be beneficial for them. Of note, ustekinumab may have advantages over the anti-integrin antibodies for this particular role. First, it appears to act more rapidly: the benefits of ustekinumab in inducing clinical response and remission in patients who had failed or were intolerant to one or more anti-TNF agents [UNITI-1 study] were observed as early as Week 3, and persisted through Week 8.
26
Anti-integrins have a rather slower onset of action, with therapeutic benefits in patients for whom therapy with anti-TNF drugs has failed being detectable at Week 10. 55, 56 Second, ustekinumab is given subcutaneously for maintenance therapy [ie more convenient mode of administration for patients and medical staff].
On the other hand, ustekinumab could also be used as a firstline biologic [ie before TNF antagonists] in patients who have failed conventional therapy, considering its satisfactory safety profile. 22, 24, 26 However, this potential may be severely limited by cost considerations, especially because of health care budget restrictions, 57 and the recent introduction of biosimilars to infliximab [CT-P13, SB2] and to adalimumab [ABP 501]. 58 Regarding patients who suffer perianal fistulising CD, the use of infliximab should be favoured because this is the only TNF antagonist having shown efficacy in a randomised controlled trial using perianal fistula healing as the primary study endpoint. 59 In addition, a meta-analysis has suggested superiority of infliximab for the treatment of CD patients with this complication. 60 However, we should note that fistula healing was a secondary study endpoint in the CHARM trial, in which adalimumab was also more effective than placebo for fistula healing. 52, 61 Specific subpopulations of CD, such as those patients with a medical history of multiple sclerosis, those with psoriasis and CD, as well as those who have developed TNF antagonist-induced psoriasis, could be ideal candidates for ustekinumab therapy. Indeed, nine patients with CD and severe psoriasiform lesions and/or TNF antagonist-induced alopecia who were included in one study, 62 and 14 patients with CD and TNF antagonist-induced psoriasiform lesions included in a second study, 45 have been successfully treated with ustekinumab.
Finally, particular attention should be given to ustekinumab use during pregnancy and breastfeeding. In animal studies conducted in cynomolgus monkeys, 63, 64 there was no evidence of teratogenicity with exposure to ustekinumab. However, data in humans are limited. 65 As a precautionary measure, it is preferable to avoid the use of ustekinumab in pregnancy. 66 Also, it remains unknown whether the drug is excreted in human breast milk. Because of the potential for adverse reactions in nursing infants from ustekinumab, a decision on whether to discontinue lactation during treatment and up to 15 weeks after treatment, or to discontinue therapy, must be made taking into account the benefit of breastfeeding to the child and the benefit of ustekinumab therapy to the woman. 66 An evidence-based choice of biological agent, according to clinical condition, is suggested in Figure 2. 
Future Challenges
Additional research is warranted to determine where ustekinumab fits in the CD treatment algorithms. There is limited or no evidence regarding: [i] the efficacy of ustekinumab in patients with fistulising CD, which is a patient population with unmet need; [ii] its potential role as postoperative prophylaxis; [iii] whether it could be useful for patients with early-onset CD; [iv] a direct head-to-head comparison of ustekinumab versus TNF antagonists or anti-integrin drugs; [v] large post-marketing follow-up studies to re-assure the drug's longterm safety profile; and [vi] a detailed pharmacoeconomic evaluation of ustekinumab in CD.
Moreover, the currently available data on mucosal healing during/ after ustekinumab use are limited. As mucosal healing has become a therapeutic goal in CD, more data are absolutely necessary. 67 Similarly, the clinical benefit of trough levels and subsequent dose escalation during ustekinumab treatment has to be investigated. 67 Further clinical evidence is also needed to clarify whether concomitant immunosuppressant therapy increases the efficacy of ustekinumab treatment. In the GETAID cohort, 45 concomitant use of immunosuppressants was a predictive factor of higher efficacy. However, this important finding was not confirmed in a second realworld study. 43 Given that immunogenicity rates with ustekinumab use appear to be low, 26 the question of whether to add or continue an immunosuppressant in combination with ustekinumab therapy remains unanswered for now.
Finally, we should note that apart from ustekinumab, many biological agents targeting the IL-23 axis are currently being studied. Some positive clinical data from phase 2 studies in CD patients have been already presented on risankizumab and MEDI2070. These agents are more specific for blocking IL-23 because they bind the p19 subunit, which is found only in IL-23. However, more research is warranted to evaluate their efficacy and safety profiles. 68 
Conclusions
Ustekinumab is a human monoclonal antibody that blocks the biological activity of IL-12 and IL-23, and thus downregulates aspects of the immune system that are important for intestinal inflammation. Data from randomised controlled trials and real-world observational studies show that this novel agent is clinically effective and reasonably safe for the management of patients with moderate-to-severe CD, with a significant body of reassuring safety data also reported from studies in patients with psoriasis and multiple sclerosis.
Ustekinumab is an appealing treatment option for patients who have an inadequate response with, lost response to, are intolerant to, or have medical contraindications to treatment with a TNF antagonist. Nevertheless, it could also be used as a first-line biologic in patients who failed conventional therapy, although its cost would probably be a significant barrier.
More high-quality evidence is required to determine how this new promising drug will be positioned into treatment algorithms for CD.
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